🚀 VC round data is live in beta, check it out!
Zentalis Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zentalis Pharma and similar public comparables like Avalo Therapeutics, NervGen Pharma, Cybin, Clinuvel Pharmaceuticals and more.
Zentalis Pharma Overview
About Zentalis Pharma
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Founded
2014
HQ
Employees
166
Website
Financials (LTM)
EV
$118M
Zentalis Pharma Financials
Zentalis Pharma reported last 12-month revenue of — and negative EBITDA of ($159M).
In the same LTM period, Zentalis Pharma generated — in gross profit, ($159M) in EBITDA losses, and had net loss of ($142M).
Revenue (LTM)
Zentalis Pharma P&L
In the most recent fiscal year, Zentalis Pharma reported revenue of — and EBITDA of ($144M).
Zentalis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($159M) | XXX | ($144M) | XXX | XXX | XXX |
| Net Profit | ($142M) | XXX | ($137M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zentalis Pharma Stock Performance
Zentalis Pharma has current market cap of $328M, and enterprise value of $118M.
Market Cap Evolution
Zentalis Pharma's stock price is $4.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $328M | 0.0% | XXX | XXX | XXX | $-1.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZentalis Pharma Valuation Multiples
Zentalis Pharma trades at (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Zentalis Pharma Financial Valuation Multiples
As of April 20, 2026, Zentalis Pharma has market cap of $328M and EV of $118M.
Equity research analysts estimate Zentalis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zentalis Pharma has a P/E ratio of (2.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $328M | XXX | $328M | XXX | XXX | XXX |
| EV (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV/EBITDA | (0.7x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/EBIT | (0.8x) | XXX | (0.8x) | XXX | XXX | XXX |
| P/E | (2.3x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zentalis Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zentalis Pharma Margins & Growth Rates
Zentalis Pharma's revenue in the last fiscal year declined by (100%).
Zentalis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Zentalis Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zentalis Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zentalis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| NervGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Cybin | XXX | XXX | XXX | XXX | XXX | XXX |
| Clinuvel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ourofino | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zentalis Pharma M&A Activity
Zentalis Pharma acquired XXX companies to date.
Last acquisition by Zentalis Pharma was on XXXXXXXX, XXXXX. Zentalis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zentalis Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZentalis Pharma Investment Activity
Zentalis Pharma invested in XXX companies to date.
Zentalis Pharma made its latest investment on XXXXXXXX, XXXXX. Zentalis Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zentalis Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zentalis Pharma
| When was Zentalis Pharma founded? | Zentalis Pharma was founded in 2014. |
| Where is Zentalis Pharma headquartered? | Zentalis Pharma is headquartered in United States. |
| How many employees does Zentalis Pharma have? | As of today, Zentalis Pharma has over 166 employees. |
| Who is the CEO of Zentalis Pharma? | Zentalis Pharma's CEO is Julie M. Eastland. |
| Is Zentalis Pharma publicly listed? | Yes, Zentalis Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Zentalis Pharma? | Zentalis Pharma trades under ZNTL ticker. |
| When did Zentalis Pharma go public? | Zentalis Pharma went public in 2020. |
| Who are competitors of Zentalis Pharma? | Zentalis Pharma main competitors are Avalo Therapeutics, NervGen Pharma, Cybin, Clinuvel Pharmaceuticals. |
| What is the current market cap of Zentalis Pharma? | Zentalis Pharma's current market cap is $328M. |
| Is Zentalis Pharma profitable? | No, Zentalis Pharma is not profitable. |
| What is the current EBITDA of Zentalis Pharma? | Zentalis Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Zentalis Pharma? | Current EBITDA multiple of Zentalis Pharma is (0.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.